ConductScience.org, home

Comparison · NCT00981045-545722dd

Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population. Trial comparisons, record NCT00981045-545722dd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00981045-545722dd

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1370.1190.157wilson
Risk in group 20.1210.1050.14wilson
Risk difference, group 1 minus group 20.0157-0.01030.0418newcombe hybrid score
Risk ratio, group 1 over group 21.130.9241.38log
Odds ratio, group 1 over group 21.150.9131.45log
Number needed to treat, for one more participant with the outcome on Ferric Carboxymaltose (FCM) than on Iron Sucrose (Venofer)63.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ferric Carboxymaltose (FCM)Ferric Carboxymaltose (FCM) : 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg1751,276OG000
Group 2Iron Sucrose (Venofer)Iron Sucrose (Venofer) : 5 doses of 200 mg for a total cumulative dose of 1000 mg1561,285OG001

Outcome

Type
PRIMARY
Title
Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.
Description
The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.
Time frame
Day 120
Population

Source ClinicalTrials.gov

Trial

Title
Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function
NCT number
NCT00981045
Phases
PHASE3
Conditions
Iron Deficiency Anemia, Impaired Renal Function
Interventions
Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer)
Lead sponsor
American Regent, Inc.
Results first posted
2013-10-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00981045-545722dd